甲氨蝶呤治疗类风湿关节炎有效性与安全性的系统评价

被引：46

作者：

兰瑛

胡蝶

宋海宁

黄师婧

何琴

机构：

[1] 成都市第三人民医院西药科

来源：

中国药房 | 2016年 / 27卷 / 21期

关键词：

甲氨蝶呤; 类风湿关节炎; 有效性; 安全性; 系统评价;

D O I：

暂无

中图分类号：

R593.22 [类风湿性关节炎];

学科分类号：

100201 [内科学];

摘要：

目的:系统评价甲氨蝶呤(MTX)治疗类风湿关节炎的有效性与安全性,为临床提供循证参考。方法:计算机检索Medline、EMBase、Cochrane图书馆、Pub Med、中国期刊全文数据库、中国生物医学文献数据库(CBM)、中文科技期刊数据库和万方数据库,收集MTX治疗类风湿关节炎的随机对照试验,按纳入与排除标准筛选文献并评价偏倚风险,提取相关数据后进行系统评价。结果与结论:有效性分析纳入33篇,合计8 253例患者;安全性分析纳入53篇,合计4 803例患者。分析结果显示,MTX治疗类风湿关节炎疗效不高于来氟米特,优于环孢素A,与柳氮磺吡啶相似;与生物制剂比较,除疗效不及托珠单抗外,与依那西普(每周7.5～20 mg)、戈利木单抗、阿达木单抗、利妥昔单抗相似。MTX不良反应发生率高,但主要为轻中度症状,最常见为消化系统不良反应。口服MTX较皮下注射和肌内注射更安全。

引用

页码：2928 / 2933

页数：6

共 29 条

[1]

Golimumab; a Human Anti–Tumor Necrosis Factor Monoclonal Antibody; Injected Subcutaneously Every 4 Weeks in Patients With Active Rheumatoid Arthritis Who Had Never Taken Methotrexate: 1‐Year and 2‐Year Clinical; Radiologic; and Physical Function Findings of a Phase III; Multicenter; Randomized; Double‐Blind; Placebo‐Controlled Study<link href="#acr22072-note-0001"/>.[J].Paul Emery;Roy M. Fleischmann;Mittie K. Doyle;Ingrid Strusberg;Patrick Durez;Peter Nash;Eric Amante;Melvin Churchill;Won Park;B

[2]

Efficacy of Leflunomide 100<ce:hsp sp="0.25"/>mg Weekly Compared to Low Dose Methotrexate in Patients With Active Rheumatoid Arthritis. Double Blind; Randomized Clinical Trial.[J].Jorge Jaimes-Hernández;Claudia Irene Meléndez-Mercado;Angélica Mendoza-Fuentes;Pablo Aranda-Pereira;Gilberto Castañeda-Hernández.Reumatología clínica (English Edition).2012, 5

[3]

A Randomized; Double-Blind; Parallel; Single-Site Pilot Trial to Compare Two Different Starting Doses of Methotrexate in Methotrexate-Na?ve Adult Patients with Rheumatoid Arthritis.[J]..Clinical Therapeutics.2012, 5

[4]

Study of active controlled tocilizumab monotherapy for rheumatoid arthritis patients with an inadequate response to methotrexate (SATORI): significant reduction in disease activity and serum vascular endothelial growth factor by IL-6 receptor inhibition therapy [J].

Nishimoto, Norihiro ;

Miyasaka, Nobuyuki ;

Yamamoto, Kazuhiko ;

Kawai, Shinichi ;

Takeuchi, Tsutomu ;

Azuma, Junichi ;

Kishimoto, Tadamitsu .

MODERN RHEUMATOLOGY, 2009, 19 (01) :12-19

[5]

Comparison of the clinical efficacy and safety of subcutaneous versus oral administration of methotrexate in patients with active rheumatoid arthritis: Results of a six‐month; multicenter; randomized; double‐blind; controlled; phase IV trial.[J]..Arthritis & Rheumatism.2007, 1

[6]

Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomised controlled trial [J].

Klareskog, L ;

van der Heijde, D ;

de Jager, JP ;

Gough, A ;

Kalden, J ;

Malaise, M ;

Mola, EM ;

Pavelka, K ;

Sany, J ;

Settas, L ;

Wajdula, J ;

Pedersen, R ;

Fatenejad, S ;

Sanda, M .

LANCET, 2004, 363 (9410) :675-681

[7]

Dose escalation of parenteral methotrexate in active rheumatoid arthritis that has been unresponsive to conventional doses of methotrexate - A randomized, controlled trial [J].

Lambert, CM ;

Sandhu, S ;

Lochhead, A ;

Hurst, NP ;

McRorie, E ;

Dhillon, V .

ARTHRITIS AND RHEUMATISM, 2004, 50 (02) :364-371

[8]

Etanercept versus methotrexate in patients with early rheumatoid arthritis - Two-year radiographic and clinical outcomes [J].

Genovese, MC ;

Bathon, JM ;

Martin, RW ;

Fleischmann, RM ;

Tesser, JR ;

Schiff, MH ;

Keystone, EC ;

Wasko, MC ;

Moreland, LW ;

Weaver, AL ;

Markenson, J ;

Cannon, GW ;

Spencer-Green, G ;

Finck, BK .

ARTHRITIS AND RHEUMATISM, 2002, 46 (06) :1443-1450

[9]

A 36 month comparative trial of methotrexate and gold sodium thiomalate in the treatment of early active ad erosive rheumatoid arthritis.[J].H Menninger;G Herborn;O Sander;J Blechsmidt;R Rau.British Journal of Rheumatology.1998,

[10]

Can collagen type II sustain a methotrexate-induced therapeutic effect in patients with long-standing rheumatoid arthritis? A double-blind; randomized trial.[J].HJ Häselmann;M Caravatti;B Seifert;K Wang;P Bruckner;G Stucki;BA Michel.British Journal of Rheumatology.1998,

← 1 2 3 →